The Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH invests from its SHS V fund in the Swiss-German specialty pharmaceuticals company Develco Pharma.
While the EU is significantly raising approval hurdles with the MDR, the US is putting medtech innovations in the fast lane with the Breakthrough Devices Program By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Putting the brakes on […]
Unquote reports on the sale of our portfolio company puracon to the precision machining business Klingel medical metal, which is a portfolio company of IK Investment Partners.
The trade magazine of going public portrays SHS (page 50-51) as one of the oldest players in the financing of German life sciences companies, start-ups and SMEs, with a focus on medical technology, diagnostics, suppliers and digital health.
The FAZ published a background article on the active M&A environment in medtech despite (and partially even supported by) the market conditions with a specific focus on the Siemens Healthineers / Varian Medical Systems transaction. Hubertus Leonhardt, managing partner of SHS, has been quoted regarding the current pricing in M&A transactions for healthcare companies.
How has the medical technology industry developed in comparison to the overall economy in recent years? The Schwäbische Zeitung (https://www.schwaebische.de) reports on the SHS Medical Technology Index.
A real improvement in kidney transplant rejection diagnostics: The transplantation of a organ (e.g. kidney) is a highly invasive procedure, a high risk but also chance for the patient and a huge burden for the body to process. Furthermore, current standards of diagnosis for the rejection risk of transplanted kidneys are invasive, not robust, and an additonal burden for the patient. This is changing now by using NMR spectroscopy as a reliable and cost efficient non invasive alternative. Would it not be good to have access to such methodology as a standard?
At MedtecLIVE, which will take place virtually for the first time on 1 July, everything will revolve around the topic of financing in medical technology, with the aim of networking the players in the medical technology sector. The programme includes live streamed lectures, talks and pitches. Among others, SHS will also be present.
FAZ reports on the SHS portfolio company Selfapy, which offers online therapies for depression, anxiety and eating disorders. This enables patients who need acute help to bridge long waiting times until a doctor’s appointment.
Dr. André Zimmermann, partner at SHS, was a guest in the BVK expert talk. Deputy Managing Director Swantje von Massenbach spoke to him about investments in the health sector, such as medical technology or diagnostics. Among other things, this included a rapid corona test that can achieve a result within 15 minutes with comparable accuracy to tests that still take several hours today. For portfolio companies and SHS investors, what is known as impact investing is particularly important. This means that investments have positive effects on health, the environment or society. You can learn more about this in the video.
With the Investor Network Tyrol, the Tyrolean location agency brings companies and start-ups together with the right investors. In a discussion between Klaus Grössinger from the Investor Network of the Tyrolean location agency and Friedrich Baldinger from the Tübingen-based medical technology and life science investor SHS, they will explain how this works in practice.
“The high demand for digital health offers should not hide the fact that the industry is facing enormous risks,” says Cornelius Maas, SHS Senior Investment Manager, in a guest article in Handelsblatt.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information